Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study

Annalisa Berzigotti, Agustín Albillos, Candid Villanueva, Joan Genescá, Alba Ardevol, Salvador Augustín, Jose Luis Calleja, Rafael Bañares, Juan Carlos García‐Pagán, Francisco Mesonero, Jaime Bosch, on behalf of the Ciberehd SportDiet Collaborative Group – 20 December 2016 – Obesity increases the risk of clinical decompensation in cirrhosis, possibly by increasing portal pressure.

Long‐term outcome in liver transplantation candidates with portopulmonary hypertension

Laurent Savale, Caroline Sattler, Audrey Coilly, Filoména Conti, Sébastien Renard, Claire Francoz, Hélène Bouvaist, Cyrille Feray, Patrick Borentain, Xavier Jaïs, David Montani, Florence Parent, Caroline O'Connell, Philippe Hervé, Marc Humbert, Gérald Simonneau, Didier Samuel, Yvon Calmus, Christophe Duvoux, François Durand, Jean Charles Duclos‐Vallée, Olivier Sitbon – 20 December 2016 – Portopulmonary hypertension (PoPH) is diagnosed in 2‐6% of liver transplantation (LT) candidates. We studied outcomes of candidates for LT suffering from PoPH.

The core domain of hepatitis C virus glycoprotein E2 generates potent cross‐neutralizing antibodies in guinea pigs

Patricia T. Vietheer, Irene Boo, Jun Gu, Kathleen McCaffrey, Stirling Edwards, Catherine Owczarek, Matthew P. Hardy, Louis Fabri, Rob J. Center, Pantelis Poumbourios, Heidi E. Drummer – 20 December 2016 – A vaccine that prevents hepatitis C virus (HCV) infection is urgently needed to support an emerging global elimination program. However, vaccine development has been confounded because of HCV's high degree of antigenic variability and the preferential induction of type‐specific immune responses with limited potency against heterologous viral strains and genotypes.

New therapeutic concepts in bile acid transport and signaling for management of cholestasis

Michael Trauner, Claudia Daniela Fuchs, Emina Halilbasic, Gustav Paumgartner – 20 December 2016 – The identification of the key regulators of bile acid (BA) synthesis and transport within the enterohepatic circulation has revealed potential targets for pharmacological therapies of cholestatic liver diseases.

New therapeutic concepts in bile acid transport and signaling for management of cholestasis

Michael Trauner, Claudia Daniela Fuchs, Emina Halilbasic, Gustav Paumgartner – 20 December 2016 – The identification of the key regulators of bile acid (BA) synthesis and transport within the enterohepatic circulation has revealed potential targets for pharmacological therapies of cholestatic liver diseases.

Subscribe to